Model Medicines Selected to Participate at the 2022 BioPharm America Event in Boston, Following Submission of a Pre-IND Briefing Document and Meeting Request to the FDA
Dr. Daniel Haders, founder and CEO of Model Medicines will be presenting at this year’s BioPharm America Conference in Boston, speaking to the recent data showing MDL-001 as a pan-antiviral drug with treatment paradigm changing potential.
The Model Medicines’ GalileoTM platform and drug hunting expertise are now responsible for one of the world’s first AI-discovered drugs to achieve this stage of development.
The company is now in an exclusive group of AI-drug discovery companies known to have discovered a small molecule therapeutic using AI and brought it to this stage of development.
Model Medicines recently completed a submission of a Pre-IND Briefing Document and Meeting Request to the FDA for MDL-001.
Model Medicines is participating in a manuscript in collaboration with research partners, Arnab Chatterjee, PhD, at California Institute for Biomedical Research (Calibr), Scripps Research, as well as Adolfo Garcia-Sastre, PhD, and Kris White, PhD, at the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine.
LA JOLLA, CA., Sept 28, 2022 -- Model Medicines, the pharmatech company working to transform the drug discovery and development industry and accelerate the creation of life-changing drugs using artificial intelligence (AI) and machine learning (ML), today announced that the company will participate in the BioPharm America conference in Boston. This announcement follows recent positive data the company recently released surrounding its pan-antiviral drug candidate, MDL-001, and their acceptance into the National Institute of Health's (NIH) Antiviral Program for Pandemics (APP).
Model Medicines discovered and developed MDL-001, a potent, orally available, direct-acting antiviral agent with an extended half-life, which makes it conducive for simplified patient dosing. The drug has previously been evaluated in Phase I clinical studies evaluating safety and tolerability in a separate indication, and no concerns were noted. Together, these characteristics make MDL-001 a candidate for the next generation of pan-antiviral drugs with treatment paradigm changing potential.
Dr. Daniel Haders, founder and CEO of Model Medicines will be participating in this year’s BioPharm America in Boston, presenting data will be the subject of a manuscript being developed in collaboration with research partners, Arnab Chatterjee, PhD, at California Institute for Biomedical Research (Calibr), Scripps Research, as well as Adolfo Garcia-Sastre, PhD, and Kris White, PhD, at the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine.
A virtual and live version of the event can be seen here: https://informaconnect.com/biopharm-america/.
ABOUT MODEL MEDICINES
Model Medicines is a pharmatech company working to transform the drug discovery and development industry by accelerating the creation of life-changing drugs using artificial intelligence and machine learning. Model Medicines was started in 2019 to deliver on the promise of AI-Drug discovery. With more than 90+ assets for 10+ targets, we are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA. www.modelmedicines.com
